3 Pharma Brand, Medical Device and Diagnostic Chain Stocks With a Strong Future Roadmap: Mankind Pharma, Poly Medicure and Suraksha Diagnostic
- October 13, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Mankind Pharma Rs 2,400.00, P/E 47.91. Poly Medicure Rs 1,641.20, P/E 51.87. Suraksha Diagnostic Rs 308.60, P/E 46.05. Closing prices of 12 Oct 2026.
Quick Answer
Pharma brand, medical device and diagnostic chain stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, Poly Medicure in infusion sets, needles, catheters and dialysis products and Suraksha Diagnostic in diagnostic and pathology testing through labs and collection centres. FY26 revenue growth was 14.8% at Mankind Pharma, 13.4% at Poly Medicure and 22.5% at Suraksha Diagnostic. P/E stands at 47.91 for Mankind Pharma (industry 37.59), 51.87 for Poly Medicure (industry 62.79) and 46.05 for Suraksha Diagnostic (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Pharma brand, medical device and diagnostic chain stocks give investors exposure to medicines, devices and tests that patients, hospitals and doctors rely on. Prescription growth, export orders and test volumes decide how much of that demand turns into profit.
This list covers three pharma brand, medical device and diagnostic chain stocks: Mankind Pharma for branded formulations across chronic and acute therapies, Poly Medicure for infusion sets, needles, catheters and dialysis products and Suraksha Diagnostic for diagnostic and pathology testing through labs and collection centres. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Brand, Medical Device and Diagnostic Chain Stocks?
Pharma brand, medical device and diagnostic chain stocks are shares of companies that make medicines and devices or run diagnostic labs. Results depend on prescription growth, export orders and test volumes, so growth and margins separate the stronger names.
Pharma Brand, Medical Device and Diagnostic Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three pharma brand, medical device and diagnostic chain stocks as of the 12 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Mankind Pharma | 2,400.00 | 99,065 | 47.91 | 37.59 | 11.74% | 0.39 |
| Poly Medicure | 1,641.20 | 16,231 | 51.87 | 62.79 | 10.37% | 0.11 |
| Suraksha Diagnostic | 308.60 | 1,614 | 46.05 | 62.79 | 13.15% | 0.53 |
Among healthcare stocks, Mankind Pharma trades at a premium to the industry P/E, while Poly Medicure and Suraksha Diagnostic trade at a discount.
Why Do Pharma Brand, Medical Device and Diagnostic Chain Stocks Have a Strong Roadmap in India?
Pharma brand, medical device and diagnostic chain stocks have a strong roadmap in India because health spending, hospital growth and rising use of diagnostic tests keep lifting demand for medicines, devices and labs. Three drivers stand out.
- Chronic care: Long-term therapies bring repeat prescriptions.
- Device exports: Global buyers source consumables from India.
- Testing demand: More patients and doctors rely on diagnostic reports.
Mankind Pharma: Branded Formulations Anchor the Roadmap
Mankind Pharma’s roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.
Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.
Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.
Poly Medicure: Medical Devices Build the Next Leg
Poly Medicure’s roadmap rests on medical devices such as infusion sets, needles, catheters and dialysis products sold in India and many export markets, with rising healthcare consumption and export demand supporting growth.
Revenue grew from Rs 960.97 crore in FY22 to Rs 1,995.34 crore in FY26, a 107.6% rise, and FY26 revenue was 13.4% higher than FY25. FY26 net profit was Rs 320.73 crore. In Q1 FY27, revenue grew 25.5% to Rs 558.79 crore. Operating margin was 27.65% in FY26.
Debt to equity is 0.11 and return on equity is 10.37%. FY26 operating cash flow was Rs 246.37 crore against capital expenditure of Rs 308.39 crore. Poly Medicure paid a dividend of Rs 3.5 per share for FY26, a yield of 0.22%. At a P/E of 51.87 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: The P/E of 51.87 against an industry P/E of 62.79 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline
Suraksha Diagnostic’s roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.
Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore, and net profit rose 40.0% to Rs 12.85 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.
Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.
Best Pharma Brand, Medical Device and Diagnostic Chain Stocks in India: Mankind Pharma vs Poly Medicure vs Suraksha Diagnostic on Key Financials
Among the best pharma brand, medical device and diagnostic chain stocks in India, Mankind Pharma ranks second on FY26 revenue growth and return on equity; Poly Medicure leads on Q1 FY27 revenue growth and the lowest debt to equity; Suraksha Diagnostic leads on FY26 revenue growth and FY26 operating margin. The table puts the numbers side by side.
| Metric | Mankind Pharma | Poly Medicure | Suraksha Diagnostic |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 14,636.43 | 1,995.34 | 313.58 |
| FY26 revenue growth | 14.8% | 13.4% | 22.5% |
| FY26 net profit (Rs Cr) | 1,938.10 | 320.73 | 31.40 |
| FY26 operating profit margin | 27.06% | 27.65% | 32.01% |
| Q1 FY27 revenue growth (YoY) | 11.7% | 25.5% | 20.7% |
| Return on equity | 11.74% | 10.37% | 13.15% |
| P/E ratio | 47.91 | 51.87 | 46.05 |
| Debt to equity | 0.39 | 0.11 | 0.53 |
| Dividend yield | 0.04% | 0.22% | 0.02% |
| FY26 operating cash flow (Rs Cr) | 3,121.29 | 246.37 | 81.83 |
Healthcare earnings follow prescription growth, export orders and test volumes, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Pharma Brand, Medical Device and Diagnostic Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen pharma brand, medical device and diagnostic chain stocks and shortlist pharma brand, medical device and diagnostic chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Pharma Brand, Medical Device and Diagnostic Chain Stocks
- Pricing rules: Price controls can affect margins.
- Competition: Rival brands and labs can pressure growth.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Mankind Pharma, Poly Medicure and Suraksha Diagnostic live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover branded medicines, medical devices and diagnostic labs. Mankind Pharma ranks second on FY26 revenue growth and return on equity; Poly Medicure leads on Q1 FY27 revenue growth and the lowest debt to equity; Suraksha Diagnostic leads on FY26 revenue growth and FY26 operating margin.
Across pharma brand, medical device and diagnostic chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pharma brand, medical device and diagnostic chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Pharma Brand, Medical Device and Diagnostic Chain Stocks
Which are the best pharma brand, medical device and diagnostic chain stocks in India with a strong roadmap?
Ans. Mankind Pharma, Poly Medicure and Suraksha Diagnostic stand out for their roadmaps in branded medicines, medical devices and diagnostic labs. FY26 revenue growth was 14.8% at Mankind Pharma, 13.4% at Poly Medicure and 22.5% at Suraksha Diagnostic, and return on equity ranges from 10.37% to 13.15%.
Is Mankind Pharma a good stock to buy now?
Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Mankind Pharma, Poly Medicure and Suraksha Diagnostic?
Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 51.87 for Poly Medicure (industry 62.79) and 46.05 for Suraksha Diagnostic (industry 62.79). Only Mankind Pharma trades at or above the industry multiple.
Which of these pharma brand, medical device and diagnostic chain stocks has the highest return on equity?
Ans. Suraksha Diagnostic has the highest return on equity at 13.15%, followed by Mankind Pharma at 11.74% and Poly Medicure at 10.37%.
What are the risks of investing in pharma brand, medical device and diagnostic chain stocks?
Ans. The main risks are pricing rules, competition and quarterly trends. Price controls can affect margins.
How did Mankind Pharma, Poly Medicure and Suraksha Diagnostic perform in Q1 FY27?
Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Poly Medicure reported revenue of Rs 558.79 crore, up 25.5% year on year. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year, and net profit rose 40.0% to Rs 12.85 crore.
Do pharma brand, medical device and diagnostic chain stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 0.22% for Poly Medicure and 0.02% for Suraksha Diagnostic, based on dividends declared for FY26.
How can I invest in pharma brand, medical device and diagnostic chain stocks in India?
Ans. You can buy pharma brand, medical device and diagnostic chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
